Core Insights - Fangzhou Inc. has achieved a significant milestone with the successful launch of its "XingJie" Large Language Model (XJ LLM), enhancing its AI-driven chronic disease management capabilities [2][4] - The company aims to optimize its AI models and expand its AI+H2H (Hospital-to-Home) healthcare ecosystem, integrating advanced AI technologies with professional medical services [2][6] Company Developments - Fangzhou's proprietary XJ LLM has completed the National Generative AI Service Filing, solidifying its leadership in AI-powered chronic disease management [2][4] - The dual-model architecture, consisting of XJ LLM and XS LLM, supports comprehensive management across various specialty disease areas, including weight management and psoriasis care [4][5] Technological Innovations - The XJ LLM is built on three foundational innovations: technological advancement, application transformation, and operational efficiency, which collectively enhance the service experience [3][4] - The model incorporates emotional perception and intent reasoning to better anticipate user needs, facilitating natural interactions and autonomous task execution [3][4] Strategic Partnerships - Fangzhou has established strategic partnerships with leading pharmaceutical companies such as Novo Nordisk, Innovent Biologics, and Fosun Pharma to develop frameworks for AI-enabled disease management [5] Market Position - As of June 30, 2025, Fangzhou serves 52.8 million registered users and 229,000 physicians, positioning itself as a leading online chronic disease management platform in China [7]
Fangzhou’s "XingJie” LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations